<span item_type="fundamental" item_id="00124c9b66ecaf4f0a79a7aff9c5f651" counter_id="ST/US/NAMSW" env="prod"></span><span item_type="announcement" item_id="579413260827754625" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 348 K.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -61.86 M.</p><p></p><h3>Cash Position</h3><ul><li>As of September 30, 2025, NewAmsterdam Pharma recorded cash, cash equivalents, and marketable securities of $756.0 million, compared to $834.2 million as of December 31, 2024. The decrease was primarily driven by ongoing operating expenditures.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span></li></ul><h3>Revenue</h3><ul><li>Revenue for the quarter ended September 30, 2025, was $0.3 million, compared to $29.1 million in the same period in 2024. The decrease was primarily due to the recognition of $27.3 million of revenue from a license agreement with Menarini in the prior year, with no similar milestones in the current quarter.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span></li></ul><h3>Research and Development (R&amp;D) Expenses</h3><ul><li>R&amp;D expenses were $31.0 million for the quarter ended September 30, 2025, compared to $35.7 million for the same period in 2024. This decrease was mainly due to reduced clinical and manufacturing expenses, partially offset by increased personnel expenses, including share-based compensation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span></li></ul><h3>Selling, General and Administrative (SG&amp;A) Expenses</h3><ul><li>SG&amp;A expenses were $24.5 million for the quarter ended September 30, 2025, compared to $18.4 million for the same period in 2024. The increase was primarily due to higher personnel expenses, including share-based compensation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span></li></ul><h3>Net Loss</h3><ul><li>Net loss for the quarter ended September 30, 2025, was $72.0 million, compared to a net loss of $16.6 million for the same period in 2024. The increase in net loss was due to the factors described above, along with non-cash losses related to changes in the fair value of derivative liabilities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the nine months ended September 30, 2025, was $106.9 million, compared to $121.1 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Obicetrapib demonstrated a 35-40% LDL-C lowering versus placebo as a monotherapy and approximately 50% in combination with ezetimibe. The drug also showed a 21% reduction in major adverse cardiovascular events (MACE) at one year, favoring obicetrapib.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_2.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>NewAmsterdam Pharma is focused on advancing its clinical development strategy, including the ongoing PREVAIL cardiovascular outcomes trial and the REMBRANDT Phase 3 imaging trial. The company is also preparing for the potential launch of obicetrapib, pending regulatory approval, and plans to share new efficacy and safety data at upcoming conferences.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_1.htm"></span> NewAmsterdam Pharma Company N.V. anticipates that subsequent events and developments will cause the company’s assessments to change, and it plans to continue trials until the target number of MACE events occur, which could extend beyond 2026. The company is building world-class commercial and medical science liaison functions, having doubled in size with new hires and offices in Amsterdam, Miami, and the Philadelphia metro area.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1936258/000119312525265800/nams-ex99_2.htm"></span></li></ul>

Newamsterdam Pharma - CW27 | 8-K: FY2025 Q3 Revenue: USD 348 K